PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, through a provisional agreement with Culpan Distributors Ltd.
Closes: 4pm Thursday, 13 February 2019.
We are pleased to announce a listing agreement with B. Braun New Zealand Pty Limited (“B. Braun”) for the supply of needles and syringes products to DHBs.
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit and hyperactivity disorder
We’re pleased to announce the approval of a multiproduct agreement with Teva Pharma New Zealand Limited (Teva) which will result in the following:
- funding a new pack size of modafinil (Modavigil), 60 tab pack, for narcolepsy in conjunction with a price decrease for the 30 tab pack, from 1 February 2019;
- funding a new brand of methylphenidate hydrochloride extended-release tablets (Methylphenidate ER - Teva) for attention deficit and hyperactivity disorder (ADHD) subject to the same restrictions as the Concerta and Ritalin LA brands of methylphenidate hydrochloride extended-release, following Medsafe approval;
- funding a new 40 mg formulation of glatiramer acetate (Copaxone) prefilled syringes, which would mean fewer injections for people taking this medicine, from 1 February 2019;
- delisting the current 20 mg formulation of glatiramer acetate (Copaxone) prefilled syringes from 1 July 2019.
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
We’re pleased to announce PHARMAC’s decision to approve a multiproduct agreement with Merck Sharpe & Dohme (MSD). This will result in the listing of a new, once-daily presentation of raltegravir for the treatment of HIV, once it is registered with Medsafe, as well as changes to the contractual arrangements for the currently funded presentations of raltegravir and posaconazole.
We are pleased to announce the approval of a listing agreement with NuVasive (AUST/NZ) Pty Limited (“NuVasive”) for the supply of their range of orthopaedic implants and associated products (“Orthopaedic Products”) to DHBs.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017.
We’re pleased to announce decisions to award sole supply for seven antiretroviral treatments (ARTs) used in the treatment of HIV infection.
We are pleased to announce the approval of a non-exclusive listing agreement with Omnigon Pty Ltd (“Omnigon”) for the supply of ostomy products to DHBs.
We’re pleased to announce of a listing agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of needles and syringes products.
PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for the funding of dasatinib (Sprycel) tablets for chronic myeloid leukaemia (CML) from 1 May 2019.
Closes: 5 pm on Wednesday, 30 January 2019
Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, through an agreement with AbbVie Ltd.
Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment.
We’re pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) are managed within the Pharmaceutical Schedule.
There is a change to the 2018/19 Invitation to Tender that was issued on 1 November 2018. These amendments have been uploaded to the webpage and e-portal as relevant.
PHARMAC invites proposals for the supply of various vaccines and influenza vaccines in New Zealand.
All proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4pm NZT Friday 18 January 2019 - RFx ID 20433854.
If you have any questions about this RFP, please post these on the Government Electronic Tenders Service (www.gets.govt.nz).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this RFP to be kept up to date.
We’re pleased to announce that colecalciferol oral liquid (vitamin D3, brand name Puria) will be funded in community and hospitals without restriction from 1 January 2019.
We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with BSN Medical Limited.
Decision to list Interventional Radiology products supplied by Edwards Lifesciences (New Zealand) Limited
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Edwards Lifesciences (New Zealand) Limited.
We’re pleased to announce a decision to list a new brand of iron polymaltose inj 50 mg per ml, 2 ml ampoule (Ferrosig) supplied by Sigma Healthcare.
PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners (NZ) Limited.
Closes: 5 pm on Friday, 18 January 2018